ALSO NOTED: Sankyo gains rights to diabetes drug; Ligand slashes interim CEO's salary; and much more...

> Sankyo has gained the exclusive global rights to develop, manufacture and market the new diabetes drug AJD101 and related compounds currently being developed by Ajinomoto. Release

> Ligand has slashed the salary and bonus plan for chairman and interim CEO Henry F. Blissenbach. Report

> Chutes & Ladders: DOR BioPharma has appointed Christopher J. Schaber, Ph.D., as its new president and CEO to replace Michael T. Sember. Release

> Wockhardt has received FDA approval to market cefotaxime sodium injection, a broad-spectrum antibiotic. Report

> Akorn has signed a deal in which it will manufacture injectable products for GeneraMedix, which will market the drugs under its own label. Report

And Finally… A new study concludes that Americans spent an extra $19,900 for each year of life expectancy added over the last 40 years, and the money was well spent. Article